Abcam, ab263201, Human FKBP2 knockout HEK-293T cell lysate

Size: 1Kit
FKBP2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FKBP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FKBP2 also known as FK506-binding protein 2 is a member of the immunophilin protein family and weighs approximately 15 kDa. Mechanically FKBP2 acts as a peptidyl-prolyl cis-trans isomerase facilitating the proper folding of proteins by catalyzing the interconversion between isomeric forms of proline in polypeptide chains. It is expressed mainly in the endoplasmic reticulum demonstrating strong involvement in cellular protein folding mechanisms. FKBP2 binds FK506 a macrolide with immunosuppressive properties which has identified its importance in various cell functions.
Biological function summary
FKBP2 plays significant roles in protein folding and trafficking within cells. It regulates calcium homeostasis by interacting with the calcium channels of the endoplasmic reticulum. FKBP2 often associates with complex components involved in signal transduction and cellular stress response emphasizing its roles in maintaining cellular equilibrium and reacting to external protein demands. This protein acts in coordination with other immunophilins providing a multifaceted approach to the management of protein conformation and cellular signaling.
Pathways
FKBP2 operates significantly within the protein folding and stress response pathways. It is closely related to the calcineurin signaling pathway primarily due to its interaction with immunosuppressant FK506 and its effect on calcineurin activity. In addition FKBP2 works alongside proteins like FKBP51 and HSP90 to ensure the proper functional configuration of molecular chaperones facilitating cellular adaptation under stress conditions and during protein synthesis.
FKBP2 has connections to neurodegenerative disorders and cardiovascular diseases revealing its impact on critical health concerns. Dysfunctions in FKBP2 may lead to improper protein folding linked to neurodegenerative conditions like Alzheimer's disease through its interaction with tau proteins. Furthermore its role in calcium regulation ties FKBP2 to cardiovascular disorders where any imbalance can lead to compromised cardiac function suggesting its involvement with cardiac-specific proteins such as SERCA2.